• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics wins CE mark approval for 180-day Eversense E3 CGM

June 16, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]
Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system.

Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days).

Europe already had a 180-day Senseonics CGM system available (Eversense XL), but the next-generation Eversense E3 has a number of improvements on the XL, including reduced calibrations, enhanced survivability and non-adjunctive use, meaning fingersticks aren’t necessary for dosing decisions.

Now approved in Europe, the Eversense E3 received FDA approval in February. Ascensia Diabetes Care, Senseonics’ global commercial partner, then launched the system in the U.S. on April 4 and the first patient received the E3 implantation that same week.

Ascensia will make the Eversense E3 available in Europe from the third quarter of 2022, according to a news release. It will be distributed in Germany, Italy, Spain (including Andorra), the Netherlands, Poland, Switzerland, Norway and Sweden.

Senseonics designed the Eversense E3 with proprietary sacrificial boronic acid (SBA) technology that enhances sensor longevity to make it what the company says is the longest-lasting CGM system. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.

The system also includes a removable smart transmitter, held in place with a mild silicone-based adhesive, offering discreet, on-body vibratory alerts and data transmission to a mobile app where users can view glucose values, trends and alerts.

Data presented in 2021 demonstrated strong accuracy with the fully implantable, 180-day sensor. Eversense E3 matched performance levels compared to the 90-day version, but with calibration reduced to essentially once per day. In studies, the sensor has produced a mean absolute relative difference (MARD) of 8.5%, representing high accuracy.

“The CE Mark approval for E3 is another demonstration of our commitment to advancing implantable CGM to improve the lives of more diabetes patients worldwide. Not only does E3 strengthen our position in the market, but it enables increased operational efficiency as Senseonics will now commercialize the same product iteration globally for the first time,” Senseonics President and CEO Tim Goodnow said in the release. “We are excited for Ascensia to continue to build on the momentum of the E3 launch in the U.S. as they commercialize the improved system in European markets in the coming months.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Ascensia Diabetes Care, Senseonics

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS